Stockscreener 앱 받기
4.99
0.00%
0.00
시간 외 거래:
4.98
-0.010
-0.20%
전일 마감가:
$4.99
열려 있는:
$5.1
하루 거래량:
127.25K
Relative Volume:
0.72
시가총액:
$53.82M
수익:
-
순이익/손실:
$-19.09M
주가수익비율:
-2.8034
EPS:
-1.78
순현금흐름:
$-17.24M
1주 성능:
+4.61%
1개월 성능:
+40.96%
6개월 성능:
-1.58%
1년 성능:
+17.97%
1일 변동 폭
$4.85
$5.245
1주일 범위
$4.85
$5.7441
52주 변동 폭
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
LTRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.99 | 55.43M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 109.5% - MarketBeat
Price momentum metrics for Lantern Pharma Inc. explainedHigh Confidence Strategy with Trend Alignment - Newser
Is Lantern Pharma Inc. meeting your algorithmic filter criteriaStable Profit Zone and Loss Control Analysis - Newser
What data driven models say about Lantern Pharma Inc.’s futureFree Trade Setups With Clear Risk Limits - Newser
Can volume confirm reversal in Lantern Pharma Inc.Alpha Stock Picks with Chart Confirmation - Newser
Automated trading signals detected on Lantern Pharma Inc.Free Entry Points For Growing Stocks - Newser
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial. - AInvest
Lantern Pharma Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule - citybuzz -
Lantern Pharma (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations - Barchart.com
Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Lantern Pharma Announces Release of Advanced AI Module for Blood-Brain Barrier Permeability Prediction - AI Insider
Nerdy Inc. shares rise 1.78% after-hours following Lantern Pharma's FDA clearance for GBM trial. - AInvest
How Lantern Pharma Inc. stock performs during market volatilityDaily Stock Forecast Powered by AI Tools - Newser
Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial - Barchart.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed - openPR.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Dnatrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Menafn
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Barchart.com
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U - GuruFocus
FDA Green Lights Lantern Pharma's Breakthrough Brain Cancer Drug Trial Targeting $5B GBM Market - Stock Titan
Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy - Barchart.com
Lantern Pharma completes Japanese enrolment for lung cancer drug trial - Mugglehead Magazine
Lantern Pharma schließt japanische Rekrutierung für Lungenkrebsmedikamentstudie ab - Mugglehead Magazine
Real Time Chart Alerts Flash Bullish on Lantern Pharma Inc.Swing Trade Plans Emphasize Risk Management - metal.it
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - 01net
Lantern Pharma Announces Public Release of AI Module for Blood-Brain Barrier Permeability Prediction - AInvest
How strong is Lantern Pharma Inc. company’s balance sheetNavigate market volatility with smart strategies - Jammu Links News
How does Lantern Pharma Inc. generate profit in a changing economyGame-changing returns - Jammu Links News
Is Lantern Pharma Inc. stock overvalued or undervaluedExceptional growth trajectory - Jammu Links News
What are analysts’ price targets for Lantern Pharma Inc. in the next 12 monthsUnlock your trading potential today - Jammu Links News
How volatile is Lantern Pharma Inc. stock compared to the marketAchieve rapid capital gains with smart investing - Jammu Links News
What makes Lantern Pharma Inc. stock price move sharplyRapid wealth multiplication - Jammu Links News
Is it the right time to buy Lantern Pharma Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
What is the dividend policy of Lantern Pharma Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
Lantern Pharma Appoints Dr. Schalop to Board - MSN
Lantern Pharma Inc. Recovery Gathers Momentum on Chart SignalsWatchlist for Smart Swing Trading Updated - metal.it
What is Lantern Pharma Inc. company’s growth strategyBeginner Investor Report With Low Risk - Jammu Links News
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan - Yahoo Finance
Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan - Barchart.com
Lantern Pharma's Strategic Expansion in Japan: A Catalyst for Near-Term Stock Appreciation - AInvest
Lantern Pharma (LTRN) Concludes Phase 2 Trial Enrollment in Japa - GuruFocus
Lantern Pharma shares rise 8.23% premarket after completing targeted enrollment for lung cancer trial in Japan. - AInvest
Lantern Pharma completes Japanese enrollment in lung cancer trial By Investing.com - Investing.com Australia
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 - Business Wire
Short Interest Drops in Lantern Pharma Inc. After RallyEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Why Lantern Pharma Inc. stock attracts strong analyst attentionRisk Limited High Gain Trades - beatles.ru
Lantern Pharma Inc. shares rise 5.68% premarket after a positive market sentiment. - AInvest
Lantern Pharma Inc. Could See a Relief Rally From SupportSwing Trade Plans Emphasize Risk Management - metal.it
Applying Wyckoff theory to Lantern Pharma Inc. stockInvestment Plan With Growth Optimization Finalized - metal.it
Lantern Pharma appoints Lee T. Schalop, M.D. to board and amends quorum rules - Investing.com Nigeria
Lantern Pharma appoints Lee T. Schalop, M.D. to board and amends quorum rules By Investing.com - Investing.com South Africa
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):